[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-445695-105":3,"detail-sidebar-cat-0-en-105":80,"doc-detail-445695-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":73,"head_meta":75,"extra_data":77,"updated_unix":79},105,"en","pd92-procedures-for-disinvestment-of-health-technologies-in-latin-america","PD92 Procedures For Disinvestment Of Health Technologies In Latin America","","Reallocation of resources to efficacious and safe health technologies (HT) through disinvestment strategies is critical for efficient health-system budgeting. The work identifies HT disinvestment strategies across Latin American countries and documents the procedures used. Representatives from agencies in 10 countries were interviewed after open questions on whether disinvestment is performed, whether procedures exist, how HT are selected, and what HT are excluded from benefits. Results show limited explicit procedures and frequent removal driven by obsolescence or newly observed adverse events.",{"@graph":14,"@context":72},[15,34,55],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/pd92-procedures-for-disinvestment-of-health-technologies-in-latin-america/445695/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/pd92-procedures-for-disinvestment-of-health-technologies-in-latin-america/445695.png","ImageObject",300,407,{"name":42,"@type":43},"Levi","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-29",true,{"@type":52,"interactionType":53,"userInteractionCount":33},"InteractionCounter",{"@type":54},"ViewAction",{"@type":56,"mainEntity":57},"FAQPage",[58,64,68],{"name":59,"@type":60,"acceptedAnswer":61},"What is the main objective of the study on disinvestment in Latin America?","Question",{"text":62,"@type":63},"To identify health technology (HT) disinvestment strategies in Latin American countries and to describe the procedures used.","Answer",{"name":65,"@type":60,"acceptedAnswer":66},"How were country information and procedures collected?",{"text":67,"@type":63},"Representatives of agencies from 10 Latin American countries were interviewed during the 15th RedETSA meeting in November 2024, answering open questions about disinvestment and its procedures.",{"name":69,"@type":60,"acceptedAnswer":70},"What did the results show about the use of explicit HT disinvestment procedures?",{"text":71,"@type":63},"Very few countries had explicit procedures. Some countries implemented disinvestment using established procedures, while others excluded HT due to obsolescence or adverse events that were previously unknown.","https://schema.org",{"og:url":32,"og:type":74,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":76,"canonical":32},"index,follow",{"doc_id":78,"site_id":7},445695,1790762919,{"code":4,"msg":81,"data":82},"success",[83,87,91,95,100,105,109,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":84,"show_sort_weight":85,"slug":86},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":88,"show_sort_weight":89,"slug":90},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":92,"show_sort_weight":93,"slug":94},"Exam",70,"exam",{"id":96,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},5,"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":107,"slug":108},7,40,"healthcare",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},8,"Research & Report",30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":96,"slug":129},19,"General","general",{"code":4,"msg":81,"data":131},{"doc_id":78,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":106,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":33,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":22,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":30,"preview_page_count":4},7971461740909,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","PD92 Procedures For Disinvestment Of Health Technologies In Latin America  \nMagdalena Irisarri, Ana Deminco,  \nJavier Pintos ([javier.pintos@protonmail.com](javier.pintos@protonmail.com)), Alejandra Croci, Alejandra Ferrari, Gervasio Cabrera, Ana Pérez Galán and Alicia Alemán  \nIntroduction: The reallocation of resources to efficacious and safe health technologies (HT) using disinvestment strategies to identify technologies considered to have low health value is relevant to ensure efficient use of resources. The objective of this work was to identify HT disinvestment strategies in Latin American countries and to describe the procedures used.  \nMethods: Participants in the 15th meeting of the Health Technology Assessment Network of the Americas (RedETSA), held in November 2024, were interviewed. Representatives of agencies from 10 Latin American countries (Argentina, Chile, Colombia, Cuba, Dominican Republic, Ecuador, El Salvador, Mexico, Peru, Uruguay) answered the following open questions: (i) Is disinvestment performed in your country?; (ii) Do you have established procedures for disinvestment?;(iii) How do you select HT to be disinvested?; and (iv) What type of HT are remove from the coverage of benefits?  \nResults: Argentina and Colombia have established procedures and have used them to implement HT disinvestment. Mexico also has procedures, but they have been used rarely. El Salvador does not have explicit procedures, but mechanisms for disinvestment have been used following requests from different stakeholders. The rest of the countries do not have established procedures but have excluded HT due to obsolescence or occurrence of adverse events that were previously unknown. Health technology assessment has been used to remove coverage for obsolete technologies and indications not previously assessed. Most technologies disinvested using health technology assessment were high-priced oncological medications. Conclusions: In Latin America, very few countries have explicit procedures to identify and disinvest inefficient HT. Since the reallocation of resources is a well-known tool to improve the efficiency of health systems, it is necessary to establish well defined procedures to identify potential technologies for disinvestment and to remove their funding in the different health systems.  \nPD93 Budget Impact And Sustainability Of Development PartnershipsIn The Incorporation Of Antiretrovirals Into The Brazilian Unified Health System  \nAdson José Moreira ([adson.moreira70@gmail.com](adson.moreira70@gmail.com)),Álex Brunno do Nascimento Martins,  \nBárbara Rodrigues Alvernaz dos Santos,  \nLudmila Peres Gargano, Francisco de Assis Acurcio, Augusto Afonso Guerra Júnior and  \nJuliana Alvares-Teodoro  \nIntroduction: The preferred regimen for initiating HIV/AIDS treatment, according to the Clinical Protocol and Therapeutic Guidelines (PCDT), is tenofovir, lamivudine, and dolutegravir (TDF/3TC/ DTG) . Fiocruz, through a productive development partnership (PDP), produces these antiretrovirals, strengthening the national industry. The National Committee for Health Technology Incorporation (CONITEC) evaluated the budgetary impact of incorporating bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/ TAF) combination therapy and its effect on the sustainability of the PDP.  \nMethods: The analysis used data from the 2022 HIV Clinical Monitoring Report to identify the eligible population. The unit cost of the current regimen (TDF/3TC/DTG) was obtained from the Health Price Database, while the cost of the new regimen (BIC/FTC/TAF) was extracted from CONITEC Recommendation Report No. 675/2021 . Using a market share analysis, a moderate 10 percent annual increase in uptake of BIC/FTC/TAF was projected, reaching 50 percent by the fifth year.  \nResults: For the budget impact calculation, a total of 245,923 people aged 50 years or older who were living with HIV and/or AIDS and undergoing antiretroviral therapy were considered. The costs ","cbCaimxAFWWevG2f","https://ap.wps.com/l/cbCaimxAFWWevG2f","pdf",30244,"English","# Introduction\n# Methods\n# Results\n# Conclusions","[{\"question\":\"What is the main objective of the study on disinvestment in Latin America?\",\"answer\":\"To identify health technology (HT) disinvestment strategies in Latin American countries and to describe the procedures used.\"},{\"question\":\"How were country information and procedures collected?\",\"answer\":\"Representatives of agencies from 10 Latin American countries were interviewed during the 15th RedETSA meeting in November 2024, answering open questions about disinvestment and its procedures.\"},{\"question\":\"What did the results show about the use of explicit HT disinvestment procedures?\",\"answer\":\"Very few countries had explicit procedures. Some countries implemented disinvestment using established procedures, while others excluded HT due to obsolescence or adverse events that were previously unknown.\"}]","PD92 Procedures For Disinvestment Of Health Technologies In Latin America | PDF",1790712572]